Xsensio has successfully closed an oversubscribed $7 million Series A financing round, led by WI Harper, with participation from Privilège Ventures, the European Innovation Council, and private investors across the United States, Europe, and Asia.

Xsensio is a Swiss deep‑tech company pioneering near real‑time continuous biochemical monitoring. The new funding will accelerate the development and clinical validation of its Lab‑on‑Skin® wearable biosensing platform, designed to use nanotechnology to provide dynamic biochemical information to support clinical decision‑making in hospitals and beyond.

“This Series A marks a pivotal step in translating continuous biochemical monitoring into real clinical environments,” said Esmeralda Megally, CEO of Xsensio. “For the first time, clinicians can access key continuous biochemical data in real time, information that has historically been unavailable at the point of care.”

Alongside the financing, Xsensio announced a long‑term collaboration with Texas Instruments, strengthening the company’s pathway to scalable semiconductor integration, miniaturisation, and manufacturability of its biosensing systems.

Commenting on the investment, Wilson Wu, Partner at WI Harper, said:

“We believe Xsensio is defining a new category in wearable health-tech. Continuous biochemical monitoring represents a major shift from intermittent measurements like blood tests, and can provide real‑time insight to medical practitioners. Xsensio is uniquely positioned to lead this transformation.”

WI Harper looks forward to continuing to support Xsensio as it advances toward clinical trials, testing and deployment in its next phase of growth.